Literature DB >> 25773193

The impact of events scale: a comparison of frequency versus severity approaches to measuring cancer-specific distress.

John M Salsman1,2, Benjamin D Schalet1, Michael A Andrykowski3, David Cella1,2.   

Abstract

OBJECTIVE: The Impact of Events Scale (IES) is one of the most widely used measures of event-specific distress. The IES assesses the frequency with which respondents experience intrusive thoughts and avoidant behaviors over the past week. Our aim is to demonstrate the benefit of a severity-based measurement approach of the IES compared with a frequency-based measurement approach.
METHODS: A mixed group of post-treatment cancer survivors (N = 325; M = 31.8 years old) completed measures assessing quality of life (Functional Assessment of Cancer Therapy-General), psychological adjustment (Mental Health Inventory), and cancer-related distress (IES). The IES was keyed to the cancer experience and administered with standard (frequency) and modified (severity) response options.
RESULTS: Classical reliability analyses and bifactor modeling were conducted on both versions of the IES. Reliability estimates suggest that the IES severity items were more highly intercorrelated than the IES frequency items. Both versions of the IES were highly correlated (r = 0.82), showing the presence of a dominant general factor. Bifactor modeling suggested that the severity items generally provided higher levels of discrimination than the frequency items. Validity correlations with the Functional Assessment of Cancer Therapy-General and Mental Health Inventory demonstrated that the IES severity performed as good as or better than the IES frequency.
CONCLUSIONS: Given the high correlations and similarity in content, the IES severity items largely assess the same construct as the IES frequency items. However, IES severity items generally showed improved psychometric properties and similar or higher correlations with quality of life and psychological adjustment. The IES severity approach appears to be a more informative method for assessing cancer-specific distress.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  cancer; item response theory; measurement; oncology; psychosocial; trauma

Mesh:

Year:  2015        PMID: 25773193      PMCID: PMC4568176          DOI: 10.1002/pon.3784

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  31 in total

1.  The systematic desensitization treatment of neuroses.

Authors:  J WOLPE
Journal:  J Nerv Ment Dis       Date:  1961-03       Impact factor: 2.254

2.  Reaction to trauma: a cognitive processing model.

Authors:  M Creamer; P Burgess; P Pattison
Journal:  J Abnorm Psychol       Date:  1992-08

3.  Emotional processing of fear: exposure to corrective information.

Authors:  E B Foa; M J Kozak
Journal:  Psychol Bull       Date:  1986-01       Impact factor: 17.737

4.  Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing.

Authors:  Richard C Gershon; Jin Shei Lai; Rita Bode; Seung Choi; Claudia Moy; Tom Bleck; Deborah Miller; Amy Peterman; David Cella
Journal:  Qual Life Res       Date:  2011-08-27       Impact factor: 4.147

5.  Direct and buffering effects of social support among gynecologic cancer survivors.

Authors:  Kristen M Carpenter; Jeffrey M Fowler; G Larry Maxwell; Barbara L Andersen
Journal:  Ann Behav Med       Date:  2010-02

6.  Traumatic stress symptoms among women with recently diagnosed primary breast cancer.

Authors:  Cheryl Koopman; Lisa D Butler; Catherine Classen; Janine Giese-Davis; Gary R Morrow; Joan Westendorf; Tarit Banerjee; David Spiegel
Journal:  J Trauma Stress       Date:  2002-08

Review 7.  Posttraumatic stress disorder following cancer. A conceptual and empirical review.

Authors:  Maria Kangas; Jane L Henry; Richard A Bryant
Journal:  Clin Psychol Rev       Date:  2002-05

8.  Posttraumatic growth and PTSD symptomatology among colorectal cancer survivors: a 3-month longitudinal examination of cognitive processing.

Authors:  John M Salsman; Suzanne C Segerstrom; Emily H Brechting; Charles R Carlson; Michael A Andrykowski
Journal:  Psychooncology       Date:  2009-01       Impact factor: 3.894

9.  Distress among young adult cancer survivors: a cohort study.

Authors:  Betina Yanez; Sofia F Garcia; David Victorson; John M Salsman
Journal:  Support Care Cancer       Date:  2013-04-09       Impact factor: 3.603

10.  Physical, emotional, and social health differences between posttreatment young adults with cancer and matched healthy controls.

Authors:  John M Salsman; Sofia F Garcia; Betina Yanez; Stacy D Sanford; Mallory A Snyder; David Victorson
Journal:  Cancer       Date:  2014-05-28       Impact factor: 6.860

View more
  10 in total

1.  Within-person changes in cancer-related distress predict breast cancer survivors' inflammation across treatment.

Authors:  Megan E Renna; M Rosie Shrout; Annelise A Madison; Catherine M Alfano; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William E Carson; Janice K Kiecolt-Glaser
Journal:  Psychoneuroendocrinology       Date:  2020-09-09       Impact factor: 4.905

2.  Psychosocial Resilience to Inflammation-Associated Depression: A Prospective Study of Breast-Cancer Survivors.

Authors:  Andrew W Manigault; Kate R Kuhlman; Michael R Irwin; Steve W Cole; Patricia A Ganz; Catherine M Crespi; Julienne E Bower
Journal:  Psychol Sci       Date:  2022-08-05

3.  Masculine norms about emotionality and social constraints in young and older adult men with cancer.

Authors:  Katie Darabos; Michael A Hoyt
Journal:  J Behav Med       Date:  2016-03-31

4.  Spirituality, emotional distress, and post-traumatic growth in breast cancer survivors and their partners: an actor-partner interdependence modeling approach.

Authors:  Amanda N Gesselman; Silvia M Bigatti; Justin R Garcia; Kathryn Coe; David Cella; Victoria L Champion
Journal:  Psychooncology       Date:  2016-07-04       Impact factor: 3.894

5.  MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.

Authors:  Nadine Rayes; Deborah J Bowen; Tara Coffin; Denise Nebgen; Christine Peterson; Mark F Munsell; Kathleen Gavin; Rebecca Lechner; Jamie Crase; Deborah Polinsky; Iris Romero; Stephanie V Blank; Douglas A Levine; Barbara M Norquist; Elizabeth M Swisher; Karen H Lu
Journal:  BMC Cancer       Date:  2019-07-02       Impact factor: 4.430

6.  Effect of Oral Choline Alfoscerate on Patients with Keratoconjunctivitis Sicca.

Authors:  Jin Ju Choi; Jin Sun Hwang; Young Joo Shin
Journal:  Nutrients       Date:  2020-05-23       Impact factor: 5.717

7.  Outcomes of endoscopic ultrasound as a one-off pancreatic cancer screening tool for 122 high- and moderate-risk patients.

Authors:  Marios Efthymiou; Sujievvan Chandran; Leonardo Zorron Cheng Tao Pu; Allison Collins; Anton Rajadurai; Mehrdad Nikfarjam; Rhys Vaughan
Journal:  JGH Open       Date:  2020-10-17

8.  Post-traumatic Stress Symptoms and Serotonin Transporter (5-HTTLPR) Polymorphism in Breast Cancer Patients.

Authors:  Luigi Zerbinati; Martino Belvederi Murri; Rosangela Caruso; Maria Giulia Nanni; Wendy Lam; Silvia De Padova; Silvana Sabato; Tatiana Bertelli; Giulia Schillani; Tullio Giraldi; Richard Fielding; Luigi Grassi
Journal:  Front Psychiatry       Date:  2021-04-21       Impact factor: 4.157

9.  Effect of multivitamin drug on intractable dry eye symptoms.

Authors:  Se Hie Park; Jin Sun Hwang; Young Joo Shin
Journal:  Front Med (Lausanne)       Date:  2022-09-06

10.  Distress Trajectories in Black and White Breast Cancer Survivors: From Diagnosis to Survivorship.

Authors:  Annelise A Madison; Juan Peng; M Rosie Shrout; Megan E Renna; Catherine M Alfano; Stephen P Povoski; Adele M Lipari; Doreen M Agnese; William E Carson; William B Malarkey; Janice K Kiecolt-Glaser
Journal:  Psychoneuroendocrinology       Date:  2021-05-27       Impact factor: 4.693

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.